A review of high-risk prostate cancer and the role of neo-adjuvant and adjuvant therapies

World Journal of Urology

Volumn 26, Issue 5, 2008, Pages 475-480

  Gonzalez, Joshua R ^a   Laudano, Melissa A ^a   McCann, Tara R ^a   McKiernan, James M ^a   Benson, Mitchell C ^a  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

Adjuvant therapy; High risk; Prostate; Prostatic neoplasia; Radical prostatectomy; Survival

Indexed keywords

ADJUVANT THERAPY; HUMAN; LYMPHADENECTOMY; MALE; MULTIMODALITY CANCER THERAPY; PROSTATE TUMOR; PROSTATECTOMY; REVIEW; RISK FACTOR;

COMBINED MODALITY THERAPY; HUMANS; LYMPH NODE EXCISION; MALE; NEOADJUVANT THERAPY; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 53549104403     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-008-0314-8     Document Type: Review

References (20)

1. Katz MH, McKiernan JM (2007) High-risk, clinically localized prostate cancer: Is monotherapy adequate? Rev Urol 9(Suppl 2):S19
2. Pound CR, Partin AW, Eisenberger MA et al (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281:1591
3. Tewari A, Divine G, Chang P et al (2007) Long-term survival in men with high grade prostate cancer: A comparison between conservative treatment, radiation therapy and radical prostatectomy - a propensity scoring approach. J Urol 177:911
4. Allaf ME, Palapattu GS, Trock BJ et al (2004) Anatomical extent of lymph node dissection: Impact on men with clinically localized prostate cancer. J Urol 172:1840
5. Rosser CJ, Kamat AM, Pendleton J et al (2006) Impact of fellowship training on pathologic outcomes and complication rates of radical prostatectomy. Cancer 107:54
6. Kawakami J, Meng MV, Sadetsky N et al (2006) Changing patterns of pelvic lymphadenectomy for prostate cancer: Results from CaPSURE. J Urol 176:1382
7. Messing EM, Manola J, Sarosdy M et al (1999) Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341:1781
8. Burkhard FC, Schumacher M, Studer UE (2005) The role of lymphadenectomy in prostate cancer. Nat Clin Pract Urol 2:336
9. Bader P, Burkhard FC, Markwalder R et al (2002) Is a limited lymph node dissection an adequate staging procedure for prostate cancer? J Urol 168:514
10. Steinberg GD, Epstein JI, Piantadosi S et al ((1990)) Management of stage D1 adenocarcinoma of the prostate: The Johns Hopkins experience 1974 to 1987. J Urol 144:1425
11. Catalona WJ, Miller DR, Kavoussi LR (1988) Intermediate-term survival results in clinically understaged prostate cancer patients following radical prostatectomy. J Urol 140:540
12. Daneshmand S, Quek ML, Stein JP et al (2004) Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. J Urol 172:2252
13. Gjertson CK, Asher KP, Sclar JD et al (2007) Local control and long-term disease-free survival for stage D1 (T2-T4N1-N2M0) prostate cancer after radical prostatectomy in the PSA era. Urology 70:723
14. Bolla M, van Poppel H, Collette L et al (2005) Postoperative radiotherapy after radical prostatectomy: A randomised controlled trial (EORTC trial 22911). Lancet 366:572
15. Thompson IM Jr, Tangen CM, Paradelo J et al (2006) Adjuvant radiotherapy for pathologically advanced prostate cancer: A randomized clinical trial. JAMA 296:2329
16. Hussain M, Smith DC, El-Rayes BF et al (2003) Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locallyadvanced prostate cancer. Urology 61:774
17. Kibel AS, Rosenbaum E, Kattan MW et al (2007) Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. J Urol 177:1777
18. Kibel AS (2005) An interdisciplinary approach to treating prostate cancer. Urology 65:13
19. Eastham JA, Kelly WK, Grossfeld GD et al (2003) Cancer and Leukemia Group B (CALGB) 90203: A randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. Urology 62(Suppl 1):55
20. Carducci MA, Saad F, Abrahamsson PA et al (2007) A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 110:1959